A detailed history of Mc Clarren Financial Advisors, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mc Clarren Financial Advisors, Inc. holds 83 shares of BMY stock, worth $4,414. This represents 0.05% of its overall portfolio holdings.

Number of Shares
83
Previous 1,665 95.02%
Holding current value
$4,414
Previous $91,000 24.18%
% of portfolio
0.05%
Previous 0.07%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 26, 2024

SELL
$40.25 - $52.99 $63,675 - $83,830
-1,582 Reduced 95.02%
83 $69,000
Q1 2024

Jul 26, 2024

BUY
$47.98 - $54.4 $79,886 - $90,576
1,665 New
1,665 $91,000
Q4 2023

Feb 02, 2024

BUY
$48.48 - $57.85 $76,695 - $91,518
1,582 Added 532.66%
1,879 $96,000
Q3 2023

Nov 03, 2023

BUY
$57.89 - $64.73 $173 - $194
3 Added 1.02%
297 $17,000
Q2 2023

Aug 04, 2023

SELL
$63.71 - $70.74 $19,240 - $21,363
-302 Reduced 50.67%
294 $18,000
Q1 2023

May 05, 2023

BUY
$65.71 - $74.53 $262 - $298
4 Added 0.68%
596 $40,000
Q4 2022

Jan 30, 2023

BUY
$68.48 - $81.09 $273 - $324
4 Added 0.68%
592 $42,000
Q3 2022

Oct 31, 2022

BUY
$0.13 - $76.84 $76 - $45,181
588 New
588 $41,000
Q2 2022

Aug 11, 2022

SELL
$72.62 - $79.98 $20,551 - $22,634
-283 Closed
0 $0
Q1 2022

Apr 29, 2022

BUY
$61.48 - $73.72 $61 - $73
1 Added 0.35%
283 $20,000
Q4 2021

Jan 19, 2022

BUY
$53.63 - $62.52 $160 - $187
3 Added 1.08%
282 $18,000
Q3 2021

Oct 15, 2021

SELL
$59.17 - $69.31 $11,478 - $13,446
-194 Reduced 41.01%
279 $16,000
Q2 2021

Jul 23, 2021

BUY
$61.91 - $67.42 $14,920 - $16,248
241 Added 103.88%
473 $31,000
Q1 2021

Apr 21, 2021

BUY
$59.34 - $66.74 $59 - $66
1 Added 0.43%
232 $15,000
Q4 2020

Jan 29, 2021

BUY
$57.74 - $65.43 $13,337 - $15,114
231 New
231 $14,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Mc Clarren Financial Advisors, Inc. Portfolio

Follow Mc Clarren Financial Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mc Clarren Financial Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mc Clarren Financial Advisors, Inc. with notifications on news.